News
News and events as they happenAzurity News & Events
For media inquiries email: media@azurity.com
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF KONVOMEP™ (omeprazole and sodium bicarbonate for oral suspension)
Woburn, Mass. – September 2, 2022 – Azurity Pharmaceuticals, Inc., a private pharmaceutical company focused on developing innovative dose-forms and formulations of products to serve the needs of overlooked…
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF ZONISADE™ (zonisamide oral suspension)
Woburn, Mass. – July 18, 2022 – Azurity Pharmaceuticals, Inc., a private pharmaceutical company focused on developing innovative products to serve the specific needs of overlooked…
Azurity Pharmaceuticals Announces Richard Blackburn as New CEO
Woburn, Mass. – February 18, 2022 – Azurity Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing innovative medicines that meet the specific needs of underserved…
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF FLEQSUVY™
(baclofen oral suspension)
WOBURN, MA, February 7, 2022 Azurity Pharmaceuticals, Inc., a private specialty pharmaceutical company, focused on developing innovative products to meet the unique needs of patients with underserved…
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF EPRONTIA™ (topiramate) oral solution
The first and only FDA-approved ready-to-use liquid topiramate
WOBURN, MA, November 8, 2021-Azurity Pharmaceuticals, Inc. a private specialty pharmaceutical company focused on developing innovative products to meet the unique needs of patients with underserved…
Azurity Pharmaceuticals Completes Acquisition of Arbor Pharmaceuticals
WOBURN, MA & ATLANTA, GA (September 20, 2021) – Azurity Pharmaceuticals, Inc. (“Azurity”) is pleased to announce the closing of its acquisition of Arbor Pharmaceuticals, Inc. (“Arbor”), as previously announced on August 24, 2021. The acquisition creates a leading...
Azurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of One Lot of Firvanq® (vancomycin hydrochloride for oral solution), Vancomycin 50 mg/mL Kit, Due to a Mix-Up of the Diluent Included in the Kit
FOR IMMEDIATE RELEASE – September 7, 2021 – Wilmington, MA, Azurity Pharmaceuticals, Inc. (“Azurity”) is voluntarily recalling one lot of Firvanq® (vancomycin hydrochloride for oral solution), Vancomycin 50 mg/mL Kit (“Firvanq®”) to the consumer level, as some products in the affected lot have been found to incorrectly contain a First Omeprazole (FIRST-PPI) diluent instead of the Firvanq diluent bottle.
Azurity Pharmaceuticals to Acquire and Merge with Arbor Pharmaceuticals
NovaQuest Private Equity to support the continued growth of the combined innovative, patient-centric company
WOBURN, MA & ATLANTA, GA (August 24, 2021) – Azurity Pharmaceuticals, Inc. (“Azurity”) and Arbor Pharmaceuticals, Inc. (“Arbor”) today announced they have entered into a definitive agreement in which Azurity will be acquiring Arbor from
Azurity Pharmaceuticals Announces Three New Neurology Products
WOBURN, Mass. (February 8, 2021) – Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for patients requiring customized formulations for their care, announced today the purchase of the neurology portfolio from Eton...
FDA Approves Katerzia™, the First and Only Amlodipine Oral Suspension, 1 mg/mL, for Pediatric Patients 6 Years of Age and Older
WOBURN, Mass. (July 10, 2019) – Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for patients requiring customized formulations for their care, announced today that the U.S. Food and Drug Administration (FDA) has...
CutisPharma Announces Acquisition of Silvergate Pharmaceuticals, Name Change to Azurity Pharmaceuticals
WOBURN, Mass. (June 12, 2019) – CutisPharma, Inc. announced today its acquisition of Silvergate Pharmaceuticals, Inc. and the unveiling of its new corporate brand for the unified company: Azurity Pharmaceuticals. “I am thrilled to announce the combination of two...
CutisPharma Announces FIRVANQ™
WILMINGTON, Mass. (Apr. 2, 2018) – CutisPharma announced today the commercial launch of FIRVANQ ™ (vancomycin hydrochloride) for oral solution, for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including...
NovaQuest Capital Management Acquires CutisPharma, Inc.
WILMINGTON, Mass. (Mar. 26, 2018) – CutisPharma, Inc. (“CutisPharma”), a specialty pharmaceutical company that for two decades has been the industry leader in providing innovative solutions to pharmacists, with its recently approved 505(b)(2) NDA for FIRVANQ ™...
CutisPharma announces FDA approval of FIRVANQ™
CUTISPHARMA ANNOUNCES FDA APPROVAL OF FIRVANQ™ FOR TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA (CDAD) AND STAPHYLOCOCCUS AUREUS COLITIS FDA-approved vancomycin oral liquid therapy expected to improve patient access and reduce pharmacist burden by no longer...
Arbor News & Events
Arbor Supports Updated Clinical Recommendations for Restless Legs Syndrome
Arbor has long recognized the need for effective treatment options for Restless Legs Syndrome (RLS) and support for the patients who suffer from it. We are pleased to support The Updated Algorithm for The Management of RLS developed by the Scientific and Medical...
Arbor Pharmaceuticals, LLC Confirms Availability of Triptodur® (triptorelin) for Patients with Central Precocious Puberty
Company orders additional product amid reported industry shortage ATLANTA, Aug. 25, 2020 – Arbor Pharmaceuticals, LLC, a U.S.-based specialty pharmaceutical company, today affirmed the full availability of Triptodur® (triptorelin), a twice yearly injectable...